Canaccord lowered the firm’s price target on Biodesix (BDSX) to $2.50 from $3.50 and keeps a Buy rating on the shares. The firm said its target decrease reflects multiple headwinds including tariffs, funding uncertainty, recession fears, and China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX:
- Biodesix Announces Board Member Resignations
- Biodesix, Inc. Reports Strong Growth Amid Financial Challenges
- Positive Outlook for Biodesix: Buy Rating Supported by Salesforce Improvements and Revenue Growth Opportunities
- Biodesix: Strong Financial Performance and Positive Growth Outlook Justify Buy Rating
- Biodesix: Strong Growth and Promising Future with Buy Rating from Kyle Mikson CFA